Literature DB >> 17877484

Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma.

Bruno Daniele1, Mena Annunziata, Emiddio Barletta, Vincenza Tinessa, Massimo Di Maio.   

Abstract

AIM: To assess the prognostic ability of the Cancer of the Liver Italian Program (CLIP) score in patients with hepatocellular carcinoma after a longer follow up.
METHODS: The updated survival data were derived from an analysis that was performed on two joined sets of data. The first set was collected retrospectively in 1995 and was used to perform an exploratory prognostic factor analysis (the CLIP-03 study), that produced the CLIP score. The second set of data was collected prospectively for the CLIP-01 randomized clinical trial.
RESULTS: Out of 912 overall patients, analysis was performed on 650 patients whose records contained all informationregarding prognostic factors. The median survival of the whole group of patients was 17.7 months and the 5-year survival rate was 10.7%. The median survival of the patients was inversely proportional to the CLIP score: the higher the CLIP score the worse the survival.
CONCLUSIONS: The CLIP score keeps good prognostic and discriminative abilities after a longer follow up and remains one the most useful prognostic system for hepatocellular carcinoma.

Entities:  

Year:  2007        PMID: 17877484     DOI: 10.1111/j.1872-034X.2007.00186.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  9 in total

Review 1.  Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification?

Authors:  Josep Fuster
Journal:  Hepat Oncol       Date:  2015-07-30

Review 2.  Is human hepatocellular carcinoma a hormone-responsive tumor?

Authors:  Massimo Di Maio; Bruno Daniele; Sandro Pignata; Ciro Gallo; Ermelinda De Maio; Alessandro Morabito; Maria-Carmela Piccirillo; Francesco Perrone
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

3.  TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis.

Authors:  Domenico Germano; Bruno Daniele
Journal:  Hepatobiliary Surg Nutr       Date:  2014-08       Impact factor: 7.293

4.  A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma.

Authors:  Bai-Hong Zhang; Xiang-Hui Wang; Hong-Yun Yue; Chang-Quan Ling
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-15       Impact factor: 4.553

5.  Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Ming-Chih Ho; Kiyoshi Hasegawa; Xiao-Ping Chen; Hiroaki Nagano; Young-Joo Lee; Gar-Yang Chau; Jian Zhou; Chih-Chi Wang; Young Rok Choi; Ronnie Tung-Ping Poon; Norihiro Kokudo
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

6.  Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma.

Authors:  Paul Blanc-Durand; Axel Van Der Gucht; Adrien Depeursinge; Niklaus Schaefer; Mario Jreige; Marie Nicod-Lalonde; Marina Silva-Monteiro; John O Prior; Alban Denys
Journal:  Oncotarget       Date:  2017-12-19

7.  CHRIST: CD44-Incorporated Hepatocellular Carcinoma Risk Index Scoring Tool-A Novel Prognostic Scoring System for Hepatocellular Carcinoma Development and Aggressiveness.

Authors:  Ahmed Ali Khalifa; Nermeen Abdeen; Neveen L Mikhael; Sawsan Elmalah; Ayman Elshayeb
Journal:  Medicines (Basel)       Date:  2022-02-21

Review 8.  Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy.

Authors:  Lucia Cerrito; Maria Elena Ainora; Carolina Mosoni; Raffaele Borriello; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

9.  Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents.

Authors:  Mohammed El Fayoumie; Mahmoud Abdelhady; Ahmed Gawish; Usama Hantour; Ismail Abdelkhaleek; Mohamed Abdelraheem; Alaa Alsawak; Ahmed Alwassief; Ashraf Elbahrawy
Journal:  Gastrointest Tumors       Date:  2020-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.